SCHEMBL19496544

SCHEMBL19496544

CCN1C(=O)c2ccccc2N(C)c2nc(C)ncc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK7 Q13164 8/20 0.52
▸ LRRK2 Q5S007 8/20 0.51
▸ DCLK1 O15075 8/20 0.51
▸ BRD4 O60885 3/20 0.51
▸ ALDH1A1 P00352 4/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CASP1 P29466 1/20 0.46
▸ MPI P34949 1/20 0.46
▸ CACNA1B Q00975 1/20 0.46
▸ APBA1 Q02410 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ PIK3CD O00329 3/20 0.43
▸ AURKA O14965 3/20 0.43
▸ PIK3C2G O75747 3/20 0.43
▸ PIK3CG P48736 3/20 0.43
▸ AURKB Q96GD4 3/20 0.43
▸ DRD2 P14416 2/20 0.42
▸ HTR6 P50406 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ CHRM2 P08172 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20094162 0.86 MAPK7 (0.51) MAPK7LRRK2DCLK1BRD4ALDH1A1
SCHEMBL17721092 0.85 MAPK7 (0.57) MAPK7LRRK2DCLK1BRD4PIK3CD
SCHEMBL9370046 0.79 BRD4 (0.48) MAPK7LRRK2DCLK1BRD4ALDH1A1
SCHEMBL9372896 0.78 ALDH1A1 (0.47) MAPK7LRRK2DCLK1BRD4ALDH1A1
SCHEMBL21311761 0.76 MAPT (0.67) ALDH1A1HPGDCASP1MPICACNA1B
SCHEMBL20094144 0.76 DCLK1 (0.80) MAPK7LRRK2DCLK1BRD4PIK3CD
SCHEMBL20094196 0.75 LRRK2 (0.76) MAPK7LRRK2DCLK1BRD4
SCHEMBL20094177 0.75 PIK3CG (0.80) MAPK7LRRK2DCLK1BRD4PIK3CD
SCHEMBL22473980 0.73 ALDH1A1 (0.65) ALDH1A1HPGDCASP1MPICACNA1B
SCHEMBL8791127 0.73 BRD4 (0.48) BRD4ALDH1A1HPGDCASP1MPI

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2379559-B1 PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DISORDERS DANA FARBER CANCER INST INC (US) 2017-10-25 — — EP disclosed
Send feedback